<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2411246331
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Xevaneer 300 mg capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFDINIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="DAR ALDAWA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            DAR ALDAWA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Xevaneer</strong><sup>&reg;</sup> contains cefdinir as the active ingredient. Cefdinir is a broad spectrum semisynthetic cephalosporin antibiotic for oral administration.</p><p>The bactericidal mode of action of Cefdinir is a result of the inhibition of cell wall synthesis. Cefdinir is highly beta-lactamase stable and as a result, many organisms resistant to penicillins and some cephalosporins, due to the presence of beta-lactamases, are susceptible to Cefdinir.</p><p>Most strains of the following Gram-positive and Gram negative organisms have been shown to be susceptible to cefdinir: <em>Staphylococcus species</em>, <em>Streptococcus pneumoniae</em>, <em>Streptococcus pyogenes</em>; <em>Haemophilus influenzae</em>, <em>Haemophilus parainfluenzae</em>, <em>Moraxella catarrhalis.</em></p><p>Therefore <strong>Xevaneer</strong><sup>&reg;</sup> is indicated in the treatment of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Community-Acquired Pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute Exacerbations of Chronic Bronchitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute Maxillary Sinusitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharyngitis/Tonsillitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncomplicated skin and skin structure infections</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Xevaneer</strong><strong><sup>&Ograve;</sup></strong></p><p>&sect;&nbsp; If you are with known allergic (hypersensitive) to cefdinir, cephalosporin, penicillin group of antibiotics or any other ingredients of <strong>Xevaneer</strong><sup>&reg;</sup></p><p><strong>&nbsp;</strong></p><p><strong>Take special care with Xevaneer</strong><strong><sup>&Ograve;</sup></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had hypersensitivity to cefdinir, other cephalosporins or penicillins</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a history of colitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant you should not take cefdinir during pregnancy unless it is clearly needed (rated FDA pregnancy category B). There are no adequate and well-controlled studies have been performed in pregnant women. Cefdinir is not detected in human breast milk after administration of 600 mg doses.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have renal insufficiency the total daily dose of cefdinir should be reduced.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Skipping doses may also increase your risk of further infection that is resistant to antibiotics. Xevaneer will not treat a viral infection such as the common cold or flu.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, stop taking <strong>Xevaneer<sup>&reg;</sup></strong> and call your doctor. Do not use anti-diarrhea medicine unless your doctor tells you to.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medication can cause you to have false results with certain medical tests, including urine glucose (sugar) tests. Tell any doctor who treats you that you are using <strong>Xevaneer<sup>&reg;</sup></strong>.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Avoid using antacids or mineral supplements that contain iron within 2 hours before or after taking <strong>Xevaneer<sup>&reg;</sup></strong>. Antacids or iron can make it harder for your body to absorb cefdinir. This does not include baby formula fortified with iron.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taking cefdinir with products that contain iron may cause your stools (bowel movements) to appear red in color. If this discoloration looks like blood in your stools, call your doctor.</p><p>&nbsp;</p><p><strong>Taking other medicines, herbal or dietary supplements</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Antacids and iron supplements</strong>: You should take <strong>Xevaneer</strong><sup>&reg;</sup> at least 2 hours before or after the antacid or iron supplement.</p><p>If you are receiving cefdinir with iron containing products, you may experience reddish stool due to the formation of a non-absorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.</p><p><strong>Probenecid</strong>: Probenecid inhibits the renal excretion of cefdinir resulting in higher serum concentrations and a longer half-life.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breastfeeding</strong></p><p>If you are pregnant you should not take cefdinir during pregnancy unless it is clearly needed (rated FDA pregnancy category B). There are no adequate and well-controlled studies have been performed in pregnant women. Cefdinir is not detected in human breast milk after administration of 600 mg doses.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take <strong>Xevaneer</strong><sup>&reg;</sup> exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.</p><p><strong><em>Adults:</em></strong></p><p>The recommended daily dose of <strong>Xevaneer</strong><sup>&reg;</sup> is 600 mg. This may be given as a 300 mg capsule once every 12 hours or as two 300 mg capsules once daily.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Type of Infection</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Dosage</strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Community-Acquired Pneumonia</p></td><td style="vertical-align:top"><p>300 mg q12h</p></td><td style="vertical-align:top"><p>10 days</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Acute Exacerbations of Chronic Bronchitis</p></td><td style="vertical-align:top"><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="vertical-align:top"><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute Maxillary Sinusitis</p></td><td style="vertical-align:top"><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="vertical-align:top"><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis / tonsillitis</p></td><td style="vertical-align:top"><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="vertical-align:top"><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated skin and skin structure infections</p></td><td style="vertical-align:top"><p>300 mg q 12 h</p></td><td style="vertical-align:top"><p>10 days</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p>Cefdinir is renally excreted.</p><p><em>Adults:</em></p><p>When creatinine clearance &lt; 30 ml/min, the recommended dose of <strong>Xevaneer</strong><sup>&reg;</sup> is 300 mg given once daily.</p><p><em>Children</em>:</p><p>Pediatric patients with a creatinine clearance of &lt;30 ml/min/1.73 m<sup>2</sup> should receive <strong>Xevaneer</strong><sup>&reg;</sup> 7 mg/kg (up to 300 mg) given once daily.</p><p>If you are on haemodialysis the recommended dosage is 300 mg or 7 mg/kg every other day.</p><p><strong>&nbsp;</strong></p><p><strong>If you take more Xevaneer</strong><strong><sup>&Ograve;</sup></strong><strong><sup> </sup></strong><strong>than you should</strong></p><p>Cefdinir is removed from the body by haemodialysis. No information regarding cefdinir overdosage is available but overdosage with other &beta;-lactam antibiotics has resulted in nausea, vomiting, epigastric distress, diarrhea and convulsions.</p><p>&nbsp;</p><p><strong>If you forget to take Xevaneer</strong><strong><sup>&Ograve;</sup></strong></p><p>Do not take a double dose to make up for a forgotten dose.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, <strong>Xevaneer</strong><sup>&reg;</sup> can cause side effects, although not everybody gets them.</p><p>Side effects are mild and transient in nature; most of them being diarrhea, abdominal pain, nausea, vomiting, skin rash, transient elevation in liver enzymes.</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Xevaneer</strong><strong><sup>&Ograve;</sup></strong> after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Xevaneer</strong><strong><sup>&Ograve;</sup></strong><strong> contains</strong></p><p>Xevaneer<sup>&reg;</sup> 300 mg capsules each capsule contains 300 mg cefdinir.</p><p><strong>Inactive ingredients</strong>: Croscarmellose sodium, polyoxyl 40 stearate, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What XevaneerÒ looks like and contents of the pack
XevaneerÒ capsule is pink opaque (DAD) on one side and (CAP008) on the other. 
Xevaneer® 300 capsules available in packs of 10 capsules in HDPE Jar enclosed in a carton with an insert. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dar Al Dawa Development &amp; Investment Co. Ltd. (Na&#39;ur - Jordan)</p><p>Tel. (+962 6) 57 27 132</p><p>Fax. (+962 6) 57 27 776</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي <strong>زيفانير</strong> على المادة الفعالة سفدنير. سفدنير هو مضاد حيوي ينتمي إلى مجموعة السيفالوسبورينات نصف مخلق واسع الطيف، يعطى عن طريق الفم.</p><p>يمتلك<strong> سفدنير </strong>فاعليته القاتلة للبكتيريا عن طريق تثبيطه لعملية تخليق جدار الخلية<strong>. </strong>سفدنير ذو ثباتية عالية تجاه البيتا-لاكتاميز، ولذا فإن العديد من البكتيريا المقاومة للبنسلينات ولبعض السيفالوسبورينات كنتيجة لإفراز البيتا-لاكتاميز، تكون حساسة لسفدنير.<strong> </strong></p><p>لقد ظهرت فاعلية سفدنير ضد معظم سلالات البكتيريا موجبة وسالبة الغرام: <em>فصائل ستافلوكوكس</em>، <em>ستربتوكوكس نيومونيا</em>، <em>ستربتوكوكس بيوجينز</em>، <em>هيموفيلس انفلونزا</em>، <em>هيموفيلس بارا انفلونزا</em>، <em>موراكسيلا كاتاراليس</em>.</p><p>يوصى بإستعمال <strong>زيفانير</strong> لعلاج الحالات التالية:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئة المكتسب من المجتمع</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاقمات الحادة لالتهاب القصبات الهوائية المزمن</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجيوب الفكي الحاد</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البلعوم / اللوزتين</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد وبنية الجلد غير المعقدة</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>زيفانير</strong></p><p>إذا كنت تعاني من حساسية معروفة تجاه سفدنير، السيفالوسبورينات، البنسليات أو أي من المكونات الأخرى في زيفانير.</p><p>&nbsp;</p><p><strong>الاحتياطات</strong><strong> </strong><strong>عند</strong><strong> </strong><strong>استعمال</strong><strong> </strong><strong>زيفانير</strong></p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا حدثت لديك تفاعلات تحسسية مفرطة تجاه سفدنير، السيفالوسبورينات أو البنسلينات</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق حدوث إلتهاب في القولون لديك</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حاملا يمنع تناول سفدنير إلا إذا دعت الحاجة الواضحة لذلك (مصنف فئة &quot;ب&quot; من تصنيفات الحمل لدى دائرة الغذاء والدواء الأمريكية). لا توجد دراسات كافية ومحكمة على النساء الحوامل. لا يفرز سفدنير في حليب الأم بعد إعطاء جرعات 600 ملغم.</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قصور في وظائف الكلى يجب أن تخفض الجرعة اليومية من سفدنير</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا تناولت هذا الدواء خلال المدة التي قررها الطبيب. قد تتحسن اعراضك قبل القضاء على العدوى بشكل كامل. قد يزيد تخطي الجرعات ايضا من خطر حدوث عدوى اخرى قد تكون مقاومة للمضادات الحيوية. لا يعالج <strong>زيفانير</strong> العدوى الفيروسية مثل البرد او الانفلونزا</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تسبب المضادات الحيوية الاسهال، والذي قد يكون علامة على حدوث عدوى جديدة. في حال اصبت بإسهال مائي او يحتوي على دم، توقف عن تناول <strong>زيفانير</strong> واخبر طبيبك. لا تتناول الادوية المضادة للاسهال ما لم يخبرك الطبيب بذلك.</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي هذا الدواء الى نتائج موجبة كاذبة عند تناول بعض الادوية يشمل فحوصات غلوكوز البول (السكر). أخبر طبيبك المعالج بأنك تتناول <strong>زيفانير</strong>.</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجنب استخدام مضادات الجموضة او المكملات الغذائية التي تحتوي على الحديد خلال ساعتين من تناول زيفانير او بعد تناوله. قد يصبح امتصاص سفدنير اكثر صعوبة عند تناول مضادات الحموضة او الحديد. هذا لا يشمل طعام الاطفال المدعم بالحديد.</p><p>&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يؤدي تناول سفدنير مع المنتجات المحتوية على الحديد الى ظهور براز احمر اللون. في حال حدوث تغير اللون هذا الشبيه بالدم في البراز الخاص بك، اتصل بطبيبك.</p><p>&nbsp;</p><p><strong>التداخلات</strong><strong> </strong><strong>الدوائية</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أخذ</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>أعشاب</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مكملات</strong><strong> </strong><strong>غذائية</strong></p><p>الرجاء إخبار طبيبك او الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى حتى تلك التي يتم تناولها دون وصفة طبية.</p><p><strong>الأدوية المعدلة للحموضة و المكملات الغذائية التي تحتوي على الحديد</strong>: يجب أن تتناول <strong>زيفانير</strong> قبل أو بعد الأدوية المعدلة للحموضة أو المكملات الغذائية التي تحتوي على الحديد بساعتين على الأقل.</p><p>إذا كنت تتناول سفدنير بالتزامن مع الأدوية التي تحتوي على الحديد، قد تلاحظ أن برازك محمر؛ يرجع اللون الأحمر إلى تشكل مركبات معقدة غير قابلة للإمتصاص بين سفدنير أو منتجاته المتحللة مع الحديد في الجهاز الهضمي.</p><p><strong>بروبينيسد</strong>: بروبينيسد يمنع طرح سفدنير عن طريق الكلى وبالتالي يؤدي إلى تراكيز أعلى وعمر نصف أطول لسفدنير في الدم.</p><p>&nbsp;</p><p><strong>الحمل</strong><strong> </strong><strong>والرضاعة</strong></p><p>يمنع تناول سفدنير خلال الحمل إلا إذا دعت الحاجة الواضحة لذلك (مصنف فئة &quot;ب&quot; من تصنيفات الحمل لدى دائرة الغذاء والدواء الأمريكية). لا توجد دراسات كافية ومحكمة على النساء الحوامل. لا يفرز سفدنير في حليب الأم بعد إعطاء جرعات 600 ملغم.</p><p>إستشيري طبيبك أو الصيدلي قبل تناول أي دواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول <strong>زيفانير</strong> تماما كما وصفه طبيبك. يجب أن تقوم بإستشارة طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p><strong><em>الكبار:</em></strong></p><p>الجرعة اليومية الموصى بها من <strong>زيفانير</strong> هي 600 ملغم. يمكن أن تعطى هذه الجرعة بأخذ كبسولة 300 ملغم كل 12 ساعة أو كبسولتين 300 ملغم مرة يوميا.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>نوع العدوى</strong></p></td><td style="vertical-align:top"><p><strong>الجرعة </strong></p></td><td style="vertical-align:top"><p><strong>مدة العلاج </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>التهاب الرئة المكتسب من المجتمع</strong></p></td><td style="vertical-align:top"><p>300 ملغم كل 12 ساعة</p></td><td style="vertical-align:top"><p>10 أيام</p></td></tr><tr><td style="vertical-align:top"><p><strong>التفاقمات الحادة لالتهاب القصبات الهوائية المزمن</strong></p></td><td style="vertical-align:top"><p>300 ملغم كل 12 ساعة</p><p>او</p><p>600 ملغم كل 24 ساعة</p></td><td style="vertical-align:top"><p>10 أيام</p><p>&nbsp;</p><p>10 أيام</p></td></tr><tr><td style="vertical-align:top"><p><strong>التهاب الجيوب الفكي الحاد</strong></p></td><td style="vertical-align:top"><p>300 ملغم كل 12 ساعة</p><p>او</p><p>600 ملغم كل 24 ساعة</p></td><td style="vertical-align:top"><p>10 أيام</p><p>&nbsp;</p><p>10 أيام</p></td></tr><tr><td style="vertical-align:top"><p><strong>التهاب البلعوم / اللوزتين</strong></p></td><td style="vertical-align:top"><p>300 ملغم كل 12 ساعة</p><p>او</p><p>600 ملغم كل 24 ساعة</p></td><td style="vertical-align:top"><p>5 &ndash; 10 أيام</p><p>&nbsp;</p><p>10 أيام</p></td></tr><tr><td style="vertical-align:top"><p><strong>عدوى الجلد وبنية الجلد غير المعقدة </strong></p></td><td style="vertical-align:top"><p>300 ملغم كل 12 ساعة</p></td><td style="vertical-align:top"><p>10 أيام</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><u>القصور الكلوي</u></p><p>يطرح سفدنير من الجسم عن طريق الكلى.</p><p><em>الكبار </em></p><p>عندما تكون تصفية الكرياتينين أقل من 30 مل/دقيقة، تكون الجرعة 300 ملغم <strong>زيفانير</strong> مرة واحدة يوميا.</p><p><em>الأطفال</em></p><p>يجب إعطاء الأطفال الذين تكون تصفية الكرياتينين لديهم أقل من 30 مل/دقيقة/1.73 م<sup>2</sup>: 7 ملغم/كغم <strong>زيفانير</strong> (حتى 300 ملغم) مرة واحدة يوميا.</p><p>إذا كنت تخضع &nbsp;للديلزة الدموية تكون الجرعة 300 ملغم أو 7 ملغم/كغم يوما بعد يوم.</p><p>&nbsp;</p><p><strong>الجرعة</strong><strong> </strong><strong>الزائدة</strong><strong> </strong><strong>من</strong><strong> </strong><strong>زيفانير</strong></p><p>يتم إزالة سفدنير من الجسم عن طريق الديلزة الدموية. لا توجد معلومات كافية بخصوص فرط الجرعة في حالة سفدنير ولكن فرط الجرعة بالمضادات الحيوية البيتا-لاكتامية الأخرى قد أدت إلى حدوث غثيان، قيء، ضيق شرسوفي (فوق المعدة)، إسهال وتشنجات.</p><p>&nbsp;</p><p><strong>نسيان</strong><strong> </strong><strong>تناول</strong><strong> </strong><strong>جرعة</strong><strong> </strong><strong>زيفانير</strong></p><p>لا تقم بمضاعة الجرعة للتعويض عن الجرعة الفائتة.</p><p>إذا كان لديك أي أسئلة أخرى تتعلق بإستخدام هذا الدواء، يجب إستشارة الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن الادوية الأخرى قد يسبب <strong>زيفانير</strong> أعراض جانبية على الرغم من عدم حدوثها مع جميع المرضى.</p><p>التأثيرات الجانبية بسيطة ومؤقتة بطبيعتها<strong>. </strong>اكثرها شيوعا هي إسهال، ألم في البطن، غثيان، قيء، طفح جلدي، وارتفاع مؤقت في إنزيمات الكبد.</p><p>إذا أصبحت أي من الأعراض الجانبية خطيرة أو إذا لاحظت أي أعراض جانبية لم يتم ذكرها في هذه النشرة، الرجاء إخبار طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول أيدي الاطفال ونظرهم.</p><p>لا تستخدم كبسولات <strong>زيفانير</strong> بعد تاريخ الانتهاء المذكور على العبوة الخارجية. يدل تاريخ الانتهاء على آخر يوم في الشهر المذكور.</p><p>يحفظ على درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p>يجب عدم التخلص من الادوية في المياه العادمة او النفايات المنزلية. اسأل الصيدلي حول الطريقة السليمة للتخلص من الادوية التي لم تعد بحاجة اليها. سيساعد هذا في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هي</strong><strong> </strong><strong>محتويات </strong><strong>زيفانير</strong><strong>د</strong></p><p>تحتوي كل كبسولة من <strong>زيفانير</strong> على 300 ملغم سفدنير.</p><p><strong>المواد غير الفعالة</strong>: كروس كارميلوس صوديوم<strong>، </strong>ستيارات البولي اوكسيل 40، ستيارات الماغنيسيوم</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما</strong><strong> </strong><strong>هو</strong><strong> </strong><strong>الشكل</strong><strong> </strong><strong>الصيدلاني</strong><strong> </strong><strong>ل</strong><strong>زيفانير </strong><strong>ووصفه</strong><strong> </strong><strong>وحجم</strong><strong> </strong><strong>عبوته</strong></p><p>كبسولات <strong>زيفانير</strong> لونها وردي معتمة مرمزة بالرمز (DAD) و (CAP008) على الجهة الأخرى.</p><p>تتوافر كبسولات <strong>زيفانير</strong> بعبوات بلاستيكية تحتوي كل منها على 10 كبسولات داخل كرتونة وملحقة بنشرة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة دار الدواء للتنمية والإستثمار المساهمة المحدودة (ناعور &ndash; الأردن)</p><p>هاتف: 132 27 57 (6 962 +)</p><p>فاكس: 776 27 57 (6 962 +)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xevaneer 300 mg capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xevaneer 300 mg capsules each capsule contains 300 mg cefdinir.
For the full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xevaneer capsules are pink hard gelatin capsules printed DAD on one side and CAP008 on the other. Filled with a yellow powder. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Xevaneer (cefdinir) Capsules and are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated micro-organisms in the conditions listed below.<br />Adults and Adolescents<br />Community-Acquired Pneumonia caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Haemophilus parainfluenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;-lactamase producing strains)<br />(Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae<br />(including &beta;-lactamase producing strains), Haemophilus parainfluenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), Moraxella catarrhalis (including &beta;-lactamase producing strains).<br />Acute Maxillary Sinusitis caused by Haemophilus influenzae (including &beta;-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including &beta;-lactamase producing strains).<br />Pharyngitis/Tonsillitis caused by Streptococcus pyogenes<br />NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx.<br />Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.<br />Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including &beta;-lactamase producing strains) and Streptococcus pyogenes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsules<br />The recommended dosage and duration of treatment for infections in adults and adolescents are described in the following chart; the total daily dose for all infections is 600 mg. Once-daily dosing for 10 days is as effective as BID dosing. Once-daily dosing has not been studied in pneumonia or skin infections; therefore, Xevaneer Capsules should be administered twice daily in these infections. Xevaneer Capsules may be taken without regard to meals.<br />Adults and Adolescents (Age 13 years and Older)&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Type of Infection</p></td><td style="vertical-align:top"><p>Dosage</p></td><td style="vertical-align:top"><p>Duration</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Community-Acquired Pneumonia</p></td><td style="vertical-align:top"><p>300 mg q12h</p></td><td style="vertical-align:top"><p>10 days</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Acute Exacerbations of Chronic Bronchitis</p></td><td style="vertical-align:top"><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="vertical-align:top"><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute Maxillary Sinusitis</p></td><td style="vertical-align:top"><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="vertical-align:top"><p>10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis / tonsillitis</p></td><td style="vertical-align:top"><p>300 mg q12h</p><p>or</p><p>600 mg q24h</p></td><td style="vertical-align:top"><p>5 to 10 days</p><p>&nbsp;</p><p>10 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated skin and skin structure infections</p></td><td style="vertical-align:top"><p>300 mg q 12 h</p></td><td style="vertical-align:top"><p>10 days</p></td></tr></tbody></table><p>Patients with Renal Insufficiency<br />For adult patients with creatinine clearance &lt;30 mL/min, the dose of cefdinir should be 300 mg given once daily.<br />Creatinine clearance is difficult to measure in outpatients. However, the following formula may be used to estimate creatinine clearance (CLcr) in adult patients. For estimates to be valid, serum creatinine levels should reflect steady-state levels of renal function.<br />Males:&nbsp;𝐶𝐿𝑐𝑟=(𝑤𝑒𝑖𝑔ℎ𝑡) (140&minus;𝑎𝑔𝑒)/(72)(𝑠𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒)<br />Females: CLcr = 0.85 above value<br />Where creatinine clearance is in mL/min, age is in years, weight is in kilograms, and serum creatinine is in mg/dL.3<br />Patients on hemodialysis<br />Hemodialysis removes cefdinir from the body. In patients maintained on chronic hemodialysis, the recommended initial dosage regimen is a 300 mg or 7 mg /kg dose every other day. At the conclusion of each hemodialysis session, 300 mg (or 7mg /kg) should be given. Subsequent doses (300 mg or 7 mg /kg) are then administered every other day.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xevaneer (cefdinir) is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before therapy with cefdinir is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cefdinir,<br />other cephalosporins, penicillins, or other drugs. If cefdinir is to be given to penicillin-sensitive patients, caution should be exercised because cross-hypersensitivity among &beta;-lactam antibiotics has been clearly documented<br />Pseudomembranous colitis has been reported with nearly all antibacterial agents, including cefdinir, and may range in severity from mild- to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.<br />Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of &ldquo;antibiotic-associated colitis&rdquo;.<br />After the diagnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against<br />Clostridium difficile.<br />PRECAUTIONS<br />General<br />As with other broad-spectrum antibiotics, prolonged treatment may result in the possible emergence and overgrowth of resistant organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate alternative therapy should be administered. Cefdinir, as with other broad-spectrum antimicrobials (antibiotics), should be prescribed with caution in individuals with a history of colitis.In patients with transient or persistent renal insufficiency (creatinine clearance &lt;30 mL/min), the total daily dose of cefdinir should be reduced because high and prolonged plasma concentrations of cefdinir can result following recommended doses<br />Information for Patients<br />Antacids containing magnesium or aluminum interfere with the absorption of cefdinir. If this type of antacid is required during cefdinir therapy, Xevaneer should be taken at least 2 hours before or after the antacid.<br />Iron supplements, including multivitamins that contain iron, interfere with the absorption of cefdinir. If iron supplements are required during cefdinir therapy, Xevaneer should be taken at least 2 hours before or after the supplement.<br />Iron-fortified infant formula does not significantly interfere with the absorption of cefdinir. Therefore, Xevaneer Oral Suspension can be administered with iron fortified infant formula.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antacids: (aluminum- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox&reg; TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%. Time to reach Cmax is also prolonged by 1 hour. There are no significant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdinir. If antacids are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the antacid.<br />Probenecid: As with other _-lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.<br />Iron Supplements and Foods Fortified With Iron: Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. If iron supplements are required during cefdinir therapy, cefdinir should be taken at least 2 hours before or after the supplement. The effect of foods highly fortified with elemental iron (primarily iron-fortified breakfast cereals) on cefdinir absorption has not been studied. Concomitantly administered iron-fortified infant formula (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. Therefore, Xevaneer for Oral Suspension can be administered with iron-fortified infant formula.<br />There have been rare reports of reddish stools in patients who have received cefdinir in Japan. The reddish color is due to the formation of a nonabsorbable complex between cefdinir or its breakdown products and iron in the gastrointestinal tract.<br />Drug/Laboratory Test Interactions<br />A false-positive reaction for ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest&reg;, Benedict&rsquo;s solution, or Fehling&#39;s solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix&reg; or Tes-Tape&reg;) be used. Cephalosporins are known to occasionally induce a positive direct Coombs&rsquo; test.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day).<br />Pregnancy - Teratogenic Effects<br />Pregnancy Category B: Cefdinir was not teratogenic in rats at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day) or in rabbits at oral doses up to 10 mg/kg/day (0.7 times the human dose based on mg/kg/day, 0.23 times based on mg/m2/day). Maternal toxicity (decreased body weight gain) was observed in rabbits at the maximum tolerated dose of 10 mg/kg/day without adverse effects on offspring. Decreased body weight occurred in rat fetuses at &ge;100 mg/kg/day, and in rat offspring at &ge;32 mg/kg/day. No effects were observed on maternal reproductive parameters or offspring survival, development, behavior, or reproductive function.<br />There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.<br />Labor and Delivery<br />Cefdinir has not been studied for use during labor and delivery.<br />Nursing Mothers<br />Following administration of single 600-mg doses, cefdinir was not detected in human breast milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse effects on the ability to drive or operate machinery have not been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trials &ndash;Cefdinir Capsules (Adult and Adolescent Patients):<br />In clinical trials, 5093 adult and adolescent patients (3841 US and 1252 non-US) were treated with the recommended dose of cefdinir capsules (600 mg/day). Most adverse events were mild and self-limiting. No deaths or permanent disabilities were attributed to cefdinir. One hundred forty-seven of 5093 (3%) patients discontinued medication due to adverse events thought by the investigators to be possibly, probably, or definitely associated with cefdinir therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients were discontinued due to rash thought related to cefdinir administration.<br />In the US, the following adverse events were thought by investigators to be possibly, probably, or definitely related to cefdinir capsules in multiple-dose clinical trials (N = 3841 cefdinir-treated patients):</p><table border="1" cellspacing="0" cellpadding="0" style="width:470px"><tbody><tr><td colspan="3" style="vertical-align:top; width:467px"><p>ADVERSE EVENTS ASSOCIATED WITH CEFDINIR CAPSULES</p><p>US TRIALS IN ADULT AND ADOLESCENT PATIENTS</p><p>(N = 3275)<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Incidence &ge;1%</p></td><td style="vertical-align:top"><p>Diarrhea</p><p>Vaginal moniliasis</p><p>Nausea</p><p>Headache</p><p>Abdominal pain</p><p>Vaginitis</p></td><td style="vertical-align:top; width:190px"><p>16%</p><p>5% of women</p><p>3%</p><p>2%</p><p>1%</p><p>1% of women</p></td></tr><tr><td style="vertical-align:top"><p>Incidence &lt;1% but &gt;0.1%</p></td><td style="vertical-align:top"><p>Rash</p><p>Dyspepsia</p><p>Flatulence</p><p>Vomiting</p><p>Anorexia</p><p>Constipation</p><p>Abnormal stools</p><p>Asthenia</p><p>Dizziness</p><p>Insomnia</p><p>Leukorrhea</p><p>Pruritus</p><p>Somnolence</p></td><td style="vertical-align:top; width:190px"><p>0.9%</p><p>0.8%</p><p>0.6%</p><p>0.6%</p><p>0.3%</p><p>0.3%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2% of women</p><p>0.2%</p><p>0.2%</p></td></tr></tbody></table><p><sup>a</sup> 1469 males, 1806 females<br />The following laboratory value changes of possible clinical significance, irrespective of relationship to therapy with cefdinir, were seen during clinical trials conducted in the US:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>LABORATORY VALUE CHANGES OBSERVED WITH CEFDINIR CAPSULES US TRIALS IN ADULT AND ADOLESCENT PATIENTS</p><p>(N = 3275)</p></td></tr><tr><td style="vertical-align:top"><p>Incidence &ge;1%</p></td><td style="vertical-align:top"><p>&uarr;Gamma-glutamyltransferase</p><p>&uarr;Urine protein</p><p>&uarr;Urine red blood cells</p></td><td style="vertical-align:top"><p>1%</p><p>1%</p><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Incidence &lt;1% but &gt;0.1%</p></td><td style="vertical-align:top"><p>&uarr;Alanine aminotransferase (ALT)</p><p>&uarr;Glucose, &darr;Glucose</p><p>&uarr;Urine glucose</p><p>&uarr;White blood cells, &darr;White blood cells</p><p>&darr;Lymphocytes, &uarr;Lymphocytes</p><p>&uarr;Urine specific gravity</p><p>&darr;Bicarbonate</p><p>&uarr;Eosinophils</p><p>&uarr;Phosphorus, &darr;Phosphorus</p><p>&uarr;Aspartate aminotransferase (AST)</p><p>&uarr;Urine white blood cells</p><p>&darr;Hemoglobin</p><p>&uarr;Alkaline phosphatase</p><p>&uarr;Blood urea nitrogen (BUN)</p><p>&uarr;Bilirubin</p><p>&uarr;Lactate dehydrogenase</p><p>&uarr;Platelets</p><p>&darr;Polymorphonuclear neutrophils (PMNs)</p><p>&uarr;Potassium 0.2%</p><p>&uarr;Urine pH 0.2</p></td><td style="vertical-align:top"><p>0.9%</p><p>0.9%, 0.2%</p><p>0.9%</p><p>0.8%, 0.7%</p><p>0.8%, 0.2%</p><p>0.8%</p><p>0.6%</p><p>0.6%</p><p>0.6%, 0.3%</p><p>0.4%</p><p>0.4%</p><p>0.3%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p><p>0.2%</p></td></tr></tbody></table><p>Postmarketing Experience<br />The following adverse experiences and altered laboratory tests, regardless of their relationship to cefdinir, have been reported during extensive postmarketing experience, beginning with approval in Japan in 1991: Stevens-Johnson syndrome, toxic epidermal necrolysis, exfoliative dermatitis, erythema multiforme, erythema nodosum, conjunctivitis, stomatitis, acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, increased amylase, shock, anaphylaxis, facial and laryngeal edema, feeling of suffocation, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, melena, pseudomembranous colitis, pancytopenia, granulocytopenia, leukopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, idiopathic interstitial pneumonia, fever, acute renal failure, nephropathy, bleeding tendency, coagulation disorder, disseminated intravascular coagulation, upper GI bleed, peptic ulcer, ileus, loss of consciousness, allergic vasculitis, possible cefdinir-diclofenac interaction, cardiac failure, chest pain, myocardial infarction, hypertension, involuntary movements, and rhabdomyolysis.<br />Cephalosporin Class Adverse Events<br />The following adverse events and altered laboratory tests have been reported for cephalosporin-class antibiotics in general:<br />Allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme,<br />toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, false-positive test for urinary glucose, neutropenia, pancytopenia, and agranulocytosis. Pseudomembranous colitis symptoms may begin during or after antibiotic treatment. Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.<br />To report any side effects:<br />&minus; National Pharmacovigilance and Drug Safety Centre (NPC)<br />&minus; Fax: + 966 112057662<br />&minus; Call NPC at + 966 112038222, Exts: 2317-2356-2353-2354-2334-2340<br />&minus; Toll free phone: 8002490000<br />&minus; E-mail: npc.drug@sfda.gov.sa<br />&minus; Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600-mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other &beta;-lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis removes cefdinir from the body. This may be useful in the event of a serious toxic reaction from overdosage, particularly if renal function is compromised.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with other cephalosporins, bactericidal activity of cefdinir results from inhibition of cell wall synthesis. Cefdinir is stable in the presence of some, but not all, &beta;-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins are susceptible to cefdinir.<br />Cefdinir has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections<br />Aerobic Gram-Positive Microorganisms:<br />Staphylococcus aureus (including &beta;-lactamase producing strains)<br />NOTE: Cefdinir is inactive against methicillin-resistant staphylococci.<br />Streptococcus pneumoniae (penicillin-susceptible strains only)<br />Streptococcus pyogenes<br />Aerobic Gram-Negative Microorganisms:<br />Haemophilus influenzae (including &beta;-lactamase producing strains)<br />Haemophilus parainfluenzae (including &beta;-lactamase producing strains)<br />Moraxella catarrhalis (including &beta;-lactamase producing strains)<br />The following in vitro data are available, but their clinical significance is unknown.<br />Cefdinir exhibits in vitro minimum inhibitory concentrations (MICs) of 1 &mu;g/mL or less against (&ge;90%) strains of the following microorganisms; however, the safety and effectiveness of cefdinir in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials.<br />Aerobic Gram-Positive Microorganisms:<br />Staphylococcus epidermidis (methicillin-susceptible strains only)<br />Streptococcus agalactiae<br />Viridans group streptococci<br />NOTE: Cefdinir is inactive against Enterococcus and methicillin-resistant<br />Staphylococcus species.<br />Aerobic Gram-Negative Microorganisms:<br />Citrobacter diversus<br />Escherichia coli<br />Klebsiella pneumoniae<br />Proteus mirabilis<br />NOTE: Cefdinir is inactive against Pseudomonas and Enterobacter species.<br />Susceptibility Tests:<br />Dilution Techniques: Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of cefdinir powder. The MIC values should be interpreted according to the following criteria:<br />For organisms other than Haemophilus spp. and Streptococcus spp:</p><table border="1" cellspacing="0" cellpadding="0" style="width:278px"><tbody><tr><td style="vertical-align:top; width:120px"><p>MIC (&mu;g/mL)</p></td><td style="vertical-align:top; width:157px"><p>Interpretation</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:120px"><p>&le;11</p></td><td style="vertical-align:top; width:157px"><p>Susceptible (S)</p></td></tr><tr><td style="vertical-align:top; width:120px"><p>2</p></td><td style="vertical-align:top; width:157px"><p>Intermediate (I)</p></td></tr><tr><td style="vertical-align:top; width:120px"><p>&ge;4</p></td><td style="vertical-align:top; width:157px"><p>Resistant (R)</p></td></tr></tbody></table><p>For <em>Haemophilus </em>spp:<sup>a</sup>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>MIC (&mu;g/mL)</p></td><td style="vertical-align:top"><p>Interpretationb</p></td></tr><tr><td style="vertical-align:top"><p>&le;1</p></td><td style="vertical-align:top"><p>Susceptible (S)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>a These interpretive standards are applicable only to broth microdilution susceptibility tests with <em>Haemophilus </em>spp. using <em>Haemophilus </em>Test Medium (HTM).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>b The current absence of data on resistant strains precludes defining any results other than &ldquo;Susceptible&rdquo;. Strains yielding MIC results suggestive of a &ldquo;nonsusceptible&rdquo; category should be submitted to a reference laboratory for further testing</p></td></tr></tbody></table><p>For Streptococcus spp:<br />Streptococcus pneumoniae that are susceptible to penicillin (MIC &le;0.06 &mu;g/mL), or streptococci other than S. pneumoniae that are susceptible to penicillin (MIC &le;0.12 &mu;g/mL), can be considered susceptible to cefdinir. Testing of cefdinir against penicillin-intermediate or penicillin-resistant isolates is not recommended. Reliable interpretive criteria for cefdinir are not available.<br />A report of &ldquo;Susceptible&rdquo; indicates that the pathogen is likely to be inhibited if the<br />antimicrobial compound in the blood reaches the concentration usually achievable. A report of &ldquo;Intermediate&rdquo; indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of &ldquo;Resistant&rdquo; indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.<br />Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of laboratory procedures. Standard cefdinir powder should provide the following MIC values:&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Micro-organism</p></td><td style="vertical-align:top"><p>MIC Range (&mu;g/mL)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Escherichia coli </em>ATCC 25922</p></td><td style="vertical-align:top"><p>0.12-0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em>ATCC 49766<sup>c</sup></p></td><td style="vertical-align:top"><p>0.12-0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>ATCC 29213</p></td><td style="vertical-align:top"><p>0.12-0.5</p></td></tr></tbody></table><p><sup>c</sup> This quality control range is applicable only to H. influenzae<br />ATCC 49766 tested by a broth microdilution procedure using HTM.<br />Diffusion Techniques: Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure2 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5-&mu;g cefdinir to test the susceptibility of microorganisms to cefdinir.<br />Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5-&mu;g cefdinir disk should be interpreted according to the following criteria:<br />For organisms other than Haemophilus spp. and Streptococcus spp:<sup>d</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:359px"><tbody><tr><td style="vertical-align:top; width:173px"><p>Zone Diameter (mm)</p></td><td style="vertical-align:top; width:185px"><p>Interpretation</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:173px"><p>&ge;20</p></td><td style="vertical-align:top; width:185px"><p>Susceptible (S)</p></td></tr><tr><td style="vertical-align:top; width:173px"><p>17-19</p></td><td style="vertical-align:top; width:185px"><p>Intermediate (I)</p></td></tr><tr><td style="vertical-align:top; width:173px"><p>&le;16</p></td><td style="vertical-align:top; width:185px"><p>Resistant (R)</p></td></tr></tbody></table><p>d Because certain strains of Citrobacter, Providencia, and Enterobacter spp. have been reported to give false susceptible results with the cefdinir disk, strains of these genera should not be tested and reported with this disk.<br />For Haemophilus spp&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Zone Diameter (mm)</p></td><td style="vertical-align:top"><p>Interpretationf</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&ge;20</p></td><td style="vertical-align:top"><p>Susceptible (S)</p><p>&nbsp;</p></td></tr></tbody></table><p>e These zone diameter standards are applicable only to tests with Haemophilus spp. using HTM.2<br />f The current absence of data on resistant strains precludes defining any results other than &ldquo;Susceptible.&rdquo; Strains yielding &ldquo;MIC deleted&rdquo; results suggestive of a &ldquo;nonsusceptible&rdquo; category should be submitted to a reference laboratory for further testing.<br />For Streptococcus spp:<br />Isolates of Streptococcus pneumoniae should be tested against a 1-&mu;g oxacillin disk.<br />Isolates with oxacillin zone sizes &ge;20 mm are susceptible to penicillin and can be considered susceptible to cefdinir. Streptococci other than S. pneumoniae should be tested with a 10-unit penicillin disk. Isolates with penicillin zone sizes &ge;28 mm are susceptible to penicillin and can be considered susceptible to cefdinir.<br />As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms to control the technical aspects of laboratory<br />procedures. For the diffusion technique the 5-&mu;g cefdinir disk should provide the following zone diameters in these laboratory quality control strains:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Organism</p></td><td style="vertical-align:top"><p>Zone Diameter (mm)</p></td></tr><tr><td style="vertical-align:top"><p><em>Escherichia coli </em>ATCC 25922</p></td><td style="vertical-align:top"><p>24-28</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae </em>ATCC 49766g</p></td><td style="vertical-align:top"><p>24-31</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus </em>ATCC 25923</p></td><td style="vertical-align:top"><p>25-32</p></td></tr></tbody></table><p>g This quality control range is applicable only to testing of H. influenzae<br />ATCC 49766 using HTM.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:<br />Oral Bioavailability: Maximal plasma cefdinir concentrations occur 2 to 4 hours postdose following capsule or suspension administration. Plasma cefdinir concentrations increase with dose, but the increases are less than dose-proportional from 300 mg (7 mg/kg) to 600 mg (14 mg/kg). Following administration of suspension to healthy adults, cefdinir bioavailability is 120% relative to capsules. Estimated bioavailability of cefdinir capsules is 21% following administration of a 300 mg capsule dose, and 16% following administration of a 600 mg capsule dose. Estimated absolute bioavailability of cefdinir suspension is 25%.<br />Effect of Food: Although the rate (Cmax) and extent (AUC) of cefdinir absorption from the capsules are reduced by 16% and 10%, respectively, when given with a high-fat meal, the magnitude of these reductions is not likely to be clinically significant. Therefore, cefdinir may be taken without regard to food.<br />Cefdinir Capsules: Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 300- and 600-mg oral doses of cefdinir to adult subjects are presented in the following table:<br />Mean (&plusmn;SD) Plasma Cefdinir Pharmacokinetic Parameter<br />Values Following Administration of Capsules to Adult Subjects&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Cmax</p><p>(&mu;g/mL)</p></td><td style="vertical-align:top"><p>tmax</p><p>(hr)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>AUC</p><p>(&mu;g.hr/mL)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>300 mg</p></td><td style="vertical-align:top"><p>1.60</p><p>(0.55)</p></td><td style="vertical-align:top"><p>2.9</p><p>(0.89)</p></td><td style="vertical-align:top"><p>7.05</p><p>(2.17)</p></td></tr><tr><td style="vertical-align:top"><p>600 mg</p></td><td style="vertical-align:top"><p>2.87</p><p>(1.01)</p></td><td style="vertical-align:top"><p>3.0</p><p>(0.66)</p></td><td style="vertical-align:top"><p>11.1</p><p>&nbsp;(3.87)</p></td></tr></tbody></table><p>Cefdinir Suspension: Cefdinir plasma concentrations and pharmacokinetic parameter values following administration of single 7- and 14-mg/kg oral doses of cefdinir to pediatric subjects (age 6 months-12 years) are presented in the following table:<br />Mean (&plusmn;SD) Plasma Cefdinir Pharmacokinetic Parameter Values Following<br />Administration of Suspension to Pediatric Subjects&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Dose</p></td><td style="vertical-align:top"><p>Cmax</p><p>(&mu;g/mL)</p></td><td style="vertical-align:top"><p>tmax</p><p>(hr)</p></td><td style="vertical-align:top"><p>AUC</p><p>(&mu;g.hr/mL)</p></td></tr><tr><td style="vertical-align:top"><p>7 mg/kg</p></td><td style="vertical-align:top"><p>2.30</p><p>(0.65)</p></td><td style="vertical-align:top"><p>2.2</p><p>(0.6)</p></td><td style="vertical-align:top"><p>8.31</p><p>(2.50)</p></td></tr><tr><td style="vertical-align:top"><p>14 mg/kg</p></td><td style="vertical-align:top"><p>3.86</p><p>(0.62)</p></td><td style="vertical-align:top"><p>1.8</p><p>(0.4)</p></td><td style="vertical-align:top"><p>13.4</p><p>(2.64)</p></td></tr></tbody></table><p>Multiple Dosing: Cefdinir does not accumulate in plasma following once- or twice-daily administration to subjects with normal renal function.<br />Distribution The mean volume of distribution (Vdarea) of cefdinir in adult subjects is 0.35 L/kg (&plusmn;0.29); in pediatric subjects (age 6 months-12 years), cefdinir Vdarea is<br />0.67 L/kg (&plusmn;0.38). Cefdinir is 60% to 70% bound to plasma proteins in both adult and pediatric subjects; binding is independent of concentration.<br />Skin Blister: In adult subjects, median (range) maximal blister fluid cefdinir concentrations of 0.65 (0.33-1.1) and 1.1 (0.49-1.9) &mu;g/mL were observed 4 to 5 hours following administration of 300- and 600-mg doses, respectively. Mean (&plusmn;SD) blister Cmax and AUC (0-&infin;) values were 48% (&plusmn;13) and 91% (&plusmn;18) of corresponding plasma values.<br />Tonsil Tissue: In adult patients undergoing elective tonsillectomy, respective median tonsil tissue cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were 0.25 (0.22-0.46) and 0.36 (0.22-0.80) &mu;g/g. Mean tonsil tissue concentrations were 24% (&plusmn;8) of corresponding plasma concentrations.<br />Sinus Tissue: In adult patients undergoing elective maxillary and ethmoid sinus surgery, respective median sinus tissue cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were &lt;0.12 (&lt;0.12-0.46) and 0.21 (&lt;0.12-2.0) &mu;g/g. Mean sinus tissue concentrations were 16% (&plusmn;20) of corresponding plasma concentrations.<br />Lung Tissue: In adult patients undergoing diagnostic bronchoscopy, respective median bronchial mucosa cefdinir concentrations 4 hours after administration of single 300- and 600-mg doses were 0.78 (&lt;0.06-1.33) and 1.14 (&lt;0.06-1.92) &mu;g/mL, and were 31% (&plusmn;18) of corresponding plasma concentrations. Respective median epithelial lining fluid concentrations were 0.29 (&lt;0.3-4.73) and 0.49 (&lt;0.3-0.59) &mu;g/mL, and were 35% (&plusmn;83) of corresponding plasma concentrations.<br />Middle Ear Fluid: In 14 pediatric patients with acute bacterial otitis media, respective median middle ear fluid cefdinir concentrations 3 hours after administration of single 7- and 14-mg/kg doses were 0.21 (&lt;0.09-0.94) and 0.72 (0.14-1.42) &mu;g/mL. Mean middle ear fluid concentrations were 15% (&plusmn;15) of corresponding plasma concentrations.<br />CSF: Data on cefdinir penetration into human cerebrospinal fluid are not available.<br />Metabolism and Excretion: Cefdinir is not appreciably metabolized. Activity is primarily due to parent drug. Cefdinir is eliminated principally via renal excretion with a mean plasma elimination half-life (t&frac12;) of 1.7 (&plusmn;0.6) hours. In healthy subjects with normal renal function, renal clearance is 2.0 (&plusmn;1.0) mL/min/kg, and apparent oral clearance is 11.6 (&plusmn;6.0) and 15.5 (&plusmn;5.4) mL/min/kg following doses of 300 and 600 mg, respectively. Mean percent of dose recovered unchanged in the urine following 300- and 600-mg doses is 18.4% (&plusmn;6.4) and 11.6% (&plusmn;4.6), respectively. Cefdinir clearance is reduced in patients with renal dysfunction<br />Because renal excretion is the predominant pathway of elimination, dosage should be adjusted in patients with markedly compromised renal function or who are undergoing hemodialysis.<br />Special Populations: Patients with Renal Insufficiency: Cefdinir pharmacokinetics were investigated in 21 adult subjects with varying degrees of renal function. Decreases in cefdinir elimination rate, apparent oral clearance (CL/F), and renal clearance were approximately proportional to the reduction in creatinine clearance<br />(CLcr). As a result, plasma cefdinir concentrations were higher and persisted longer in subjects with renal impairment than in those without renal impairment. In subjects with CLcr between 30 and 60 mL/min, Cmax and t&frac12; increased by approximately 2-fold and AUC by approximately 3-fold. In subjects with CLcr &lt;30 mL/min, Cmax increased by approximately 2-fold, t&frac12; by pproximately 5-fold, and AUC by approximately 6-fold. Dosage adjustment is recommended in patients with markedly compromised renal function (creatinine clearance &lt;30 mL/min)<br />Hemodialysis: Cefdinir pharmacokinetics were studied in 8 adult subjects undergoing hemodialysis. Dialysis (4 hours duration) removed 63% of cefdinir from the body and reduced apparent elimination t&frac12; from 16 (&plusmn;3.5) to 3.2 (&plusmn;1.2) hours. Dosage adjustment is recommended in this patient population<br />Hepatic Disease: Because cefdinir is predominantly renally eliminated and not appreciably metabolized, studies in patients with hepatic impairment were not conducted.<br />It is not expected that dosage adjustment will be required in this population.<br />Geriatric Patients: The effect of age on cefdinir pharmacokinetics after a single 300-mg dose was evaluated in 32 subjects 19 to 91 years of age. Systemic exposure to cefdinir was substantially increased in older subjects (N = 16), Cmax by 44% and AUC by 86%. This increase was due to a reduction in cefdinir clearance. The apparent volume of distribution was also reduced, thus no appreciable alterations in apparent elimination half-life were observed (elderly: 2.2 &plusmn; 0.6 hours vs young: 1.8 &plusmn; 0.4 hours). Since cefdinir clearance has been shown to be primarily related to changes in renal function rather than age, elderly patients do not require dosage adjustment unless they have markedly compromised renal function (creatinine clearance &lt;30 mL/min).<br />Gender and Race: The results of a meta-analysis of clinical pharmacokinetics (N = 217) indicated no significant impact of either gender or race on cefdinir pharmacokinetics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The carcinogenic potential of cefdinir has not been evaluated. No mutagenic effects were seen in the bacterial reverse mutation assay (Ames) or point mutation assay at the hypoxanthine-guanine phosphoribosyltransferase locus (HGPRT) in V79 Chinese hamster lung cells. No clastogenic effects were observed in vitro in the structural chromosome aberration assay in V79 Chinese hamster lung cells or in vivo in the micronucleus assay in mouse bone marrow. In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m2/day).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Croscarmellose sodium, polyoxyl 40 stearate, magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&ordm;C.<br />Discard unused content 10 days after opening</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE Jar with as PP cap enclosed in a carton with an insert<br />Xevaneer Capsules is available in packs containing 10 capsules</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicines should not be disposed of via wastewater or household waste.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dar Al Dawa Development & Investment Co. Ltd.
P.O. Box 9364
Na'ur – Jordan
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/01/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>